{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:33:39Z","timestamp":1791408819431,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"am","delay-in-days":130,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R43HL118926-01A1"],"award-info":[{"award-number":["1R43HL118926-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["DP2 HL123229"],"award-info":[{"award-number":["DP2 HL123229"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL117976"],"award-info":[{"award-number":["R01 HL117976"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejphar.2017.10.035","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T13:12:08Z","timestamp":1508764328000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir"],"prefix":"10.1016","volume":"818","author":[{"given":"Miguel M.","family":"Leiva-Juarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson T.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenton","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Tuvim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burton F.","family":"Dickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Markesich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.10.035_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fphar.2014.00008","article-title":"Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands","volume":"5","author":"Alfaro","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"23","key":"10.1016\/j.ejphar.2017.10.035_bib2","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMc0910060","article-title":"Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis","volume":"361","author":"Baz","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.035_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.035_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/mi.2013.26","article-title":"Lung epithelial cells are essential effectors of inducible resistance to pneumonia","volume":"7","author":"Cleaver","year":"2014","journal-title":"Mucosal Immunol."},{"issue":"10","key":"10.1016\/j.ejphar.2017.10.035_bib5","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.1002122","article-title":"Synergistic interactions of TLR2\/6 and TLR9 induce a high level of resistance to lung infection in mice","volume":"186","author":"Duggan","year":"2011","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.035_bib6","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza \u2013 recommendations of the advisory committee on immunization practices (ACIP)","volume":"60","author":"Fiore","year":"2011","journal-title":"MMWR Recomm. Rep."},{"issue":"3\u20134","key":"10.1016\/j.ejphar.2017.10.035_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/2040206616656263","article-title":"Combination activity of neuraminidase inhibitor oseltamivir and \u03b1-tocopherol in influenza virus A (H3N2) infection in mice","volume":"24","author":"Galabov","year":"2015","journal-title":"Antivir. Chem. Chemother."},{"issue":"4","key":"10.1016\/j.ejphar.2017.10.035_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1086\/318537","article-title":"Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir","volume":"183","author":"Gubareva","year":"2001","journal-title":"J. Infect. Dis."},{"issue":"13","key":"10.1016\/j.ejphar.2017.10.035_bib9","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.297.13.1435","article-title":"Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors","volume":"297","author":"Hatakeyama","year":"2007","journal-title":"J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.ejphar.2017.10.035_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01579-07","article-title":"Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice","volume":"52","author":"Ilyushina","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ejphar.2017.10.035_bib11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3201\/eid1610.100688","article-title":"Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48h","volume":"16","author":"Inoue","year":"2010","journal-title":"Emerg. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejphar.2017.10.035_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nri3665","article-title":"Innate immunity to influenza virus infection","volume":"14","author":"Iwasaki","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"20","key":"10.1016\/j.ejphar.2017.10.035_bib13","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa0906695","article-title":"Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009","volume":"361","author":"Jain","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ejphar.2017.10.035_bib14","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.clinthera.2007.08.023","article-title":"Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial","volume":"29","author":"LaForce","year":"2007","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.035_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc0910448","article-title":"200 A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza","volume":"362","author":"Le","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejphar.2017.10.035_bib16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/501727","article-title":"Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home","volume":"21","author":"Lee","year":"2000","journal-title":"Infect. Control Hosp. Epidemiol."},{"issue":"7","key":"10.1016\/j.ejphar.2017.10.035_bib17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1182\/blood-2016-03-708511","article-title":"Inducible epithelial resistance protects mice against leukemia-associated pneumonia","volume":"128","author":"Leiva-Ju\u00e1rez","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2017.10.035_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2017.03.002","article-title":"Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses","volume":"142","author":"Leyva-Grado","year":"2017","journal-title":"Antivir. Res."},{"issue":"17","key":"10.1016\/j.ejphar.2017.10.035_bib19","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1001\/jama.2009.1583","article-title":"Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California","volume":"302","author":"Louie","year":"2009","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2017.10.035_bib20","doi-asserted-by":"crossref","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice","volume":"6","author":"Marathe","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejphar.2017.10.035_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/infdis\/jiu105","article-title":"An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality","volume":"2210","author":"Marjuki","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"27","key":"10.1016\/j.ejphar.2017.10.035_bib22","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.ejphar.2017.10.035_bib23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1046\/j.1532-5415.2001.49204.x","article-title":"Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population","volume":"49","author":"Peters","year":"2001","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.035_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa054869","article-title":"The underrecognized burden of influenza in young children","volume":"355","author":"Poehling","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2017.10.035_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.15585\/mmwr.mm6506a3","article-title":"Update: influenza activity\u2013United States, October 4, 2015-February 6, 2016","volume":"65","author":"Russell","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"18","key":"10.1016\/j.ejphar.2017.10.035_bib26","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0264-410X(98)00141-8","article-title":"Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks","volume":"16","author":"Schilling","year":"1998","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.035_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.antiviral.2012.07.002","article-title":"Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents","volume":"96","author":"Smee","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2017.10.035_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2016.10.009","article-title":"Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice","volume":"136","author":"Smee","year":"2016","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2017.10.035_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/596311","article-title":"Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children","volume":"48","author":"Stephenson","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"19","key":"10.1016\/j.ejphar.2017.10.035_bib30","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.19.19565-en","article-title":"Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom","volume":"15","author":"Strong","year":"2010","journal-title":"Eur. Surveill."},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.035_bib31","doi-asserted-by":"crossref","first-page":"e30596","DOI":"10.1371\/journal.pone.0030596","article-title":"Synergistic TLR2\/6 and TLR9 activation protects mice against lethal influenza pneumonia","volume":"7","author":"Tuvim","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejphar.2017.10.035_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ajco.12565","article-title":"Successful use of oseltamivir prophylaxis in managing a nosocomial outbreak of influenza A in a hematology and allogeneic stem cell transplant unit","volume":"13","author":"Yue","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917306842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917306842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:06:25Z","timestamp":1762142785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917306842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":32,"alternative-id":["S0014299917306842"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.10.035","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}